Print

Chiral Quest, LLC And Avantium Technologies Enter Into Collaboration On Chiral Ligand Catalysts 
10/19/2005 5:09:43 PM

STATE COLLEGE, Pa., Jan. 20 /PRNewswire-FirstCall/ -- Chiral Quest, Inc. (BULLETIN BOARD: CQST) today announced that it has entered into a partnership with Avantium Technologies to utilize Chiral Quest's array of novel chiral ligand catalysts in Avantium's high throughput experimentation and simulation technology for the biopharmaceutical and fine chemical industries.

Avantium Technologies is an innovation-based company providing rational high throughput product and process R&D solutions to the chemicals and life science industries. Its unique integrated hardware and software platform provides intrinsically scaleable solid-state characterization and chemical development thus allowing rapid and reliable scale-up to pilot plant and production. Chiral Quest offers a broad spectrum of ligands for strategically important asymmetric catalytic reactions. Inclusion of Chiral Quest's proprietary catalysts enhances Avantium's extensive library of commercially available ligands for use in its testing programs.

"We are very pleased to enter this partnership with Avantium," said Chiral Quest CEO and President, Dr. Alan Roth. "Avantium is a leading provider of product and process development services, and their decision to utilize our technology is a vote of confidence in the value and uniqueness of Chiral Quest's products."

"Chiral Quest's ligands will add great value to the diversity of our existing catalyst library and greatly benefit the development technology that we provide to our clients," said Alan Lahaise, Senior Vice President Business Development of Avantium. "Avantium is continually looking for ways to stay in the forefront of biopharmaceutical development technology and we feel that Chiral Quest's novel asymmetric technologies will help us become the leader in this field."

About Chiral Quest

Chiral Quest is a life sciences chemistry company that provides chiral products and asymmetric technologies and services to the pharmaceutical and fine chemical industries. The Company develops chemical catalysts and other products used in the synthesis of desired isomers of chiral molecules. For more information, visit http://www.chiralquest.com/.

About Avantium

Avantium Technologies is an innovation-based company providing rational high throughput product and process R&D solutions to the chemicals and life science industries. Its unique integrated hardware and software platform provides intrinsically scaleable solid-state characterisation and chemical development thus allowing rapid and reliable scale-up to pilot plant and production. Avantium collaborates with, among others, Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Mitsubishi Pharma Corporation, Shell and Eastman Chemicals. The company has its head offices and laboratory in Amsterdam (Avantium Technologies B.V.) and employs a satellite laboratory within Delft University to collaborate with the Dutch Universities in a cutting-edge discovery program. For more information, visit: http://www.avantium.com/.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause Chiral Quest's actual results and experience to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Chiral Quest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Chiral Quest assumes no obligation and does not intend to update these forward-looking statements.

Chiral Quest, Inc.

CONTACT: Alan D. Roth, Ph.D. of Chiral Quest, Inc., +1-814-234-5054; orInvestors, Ritu Baral of The Trout Group, +1-212-477-9007 ext. 25, for ChiralQuest, Inc.; or Lieven De Smedt. CBO of Avantium Technologies BV,+31-20-586-8008, or lieven.desmedt@avantium.com


//-->